» Articles » PMID: 38542521

Expression of E-Cadherin and N-Cadherin in the Endocervix As a Predictive Factor in Patients with Endometrial Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Mar 28
PMID 38542521
Authors
Affiliations
Soon will be listed here.
Abstract

Endometrial cancer (EC) is the most common gynecological malignancy. This study aimed to evaluate the expression of E-cadherin and N-cadherin in primary endometrial lesions and the endocervix in patients with EC to identify noninvasive predictive factors. In this single-center retrospective study, data on 101 patients who underwent surgery for EC were collected. The immunohistochemical expression of E-cadherin and N-cadherin was assessed depending on the tumor grade, location, and cell differentiation. Correlations between E-cadherin and N-cadherin levels in the endocervix and the primary tumor were determined. The degree of histological tumor differentiation significantly affected E-cadherin expression ( = 0.04) but had no impact on N-cadherin levels. In type II EC, the expression of both cadherins in the tumor tissue differed from their endocervical levels. The expression of E-cadherin differed significantly between the endocervix ( < 0.001) and the tumor ( = 0.001), depending on the type of EC. The expression of E-cadherin was related to the N-cadherin level only in the endocervix in patients with type II EC ( = 0.02). E-cadherin and N-cadherin were expressed in the endocervix in patients with EC. The expression of cadherins, determined during cervical cytology, may be a valuable clinical marker of EC.

Citing Articles

CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.

Hirsch R, Premsankar S, Kurnit K, Chiou L, Rabjohns E, Lee H bioRxiv. 2024; .

PMID: 39605508 PMC: 11601622. DOI: 10.1101/2024.11.18.624183.

References
1.
Chiu H, Li C, Yiang G, Tsai A, Wu M . Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial Carcinogenesis. J Clin Med. 2019; 8(4). PMC: 6518354. DOI: 10.3390/jcm8040439. View

2.
Costas L, Palomero L, Benavente Y, Guardiola M, Frias-Gomez J, Pavon M . Defining a mutational signature for endometrial cancer screening and early detection. Cancer Epidemiol. 2019; 61:129-132. DOI: 10.1016/j.canep.2019.06.003. View

3.
Lewczuk L, Pryczynicz A, Guzinska-Ustymowicz K . Expression level of E-, N- and P-cadherin proteins in endometrial cancer. Oncol Lett. 2021; 21(4):261. PMC: 7882895. DOI: 10.3892/ol.2021.12522. View

4.
. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014; 125(2):97-8. DOI: 10.1016/j.ijgo.2014.02.003. View

5.
Ma X, Ge A, Han J, Kang J, Zhang Y, Liu X . Meta-analysis of downregulated E-cadherin as a diagnostic biomarker for cervical cancer. Arch Gynecol Obstet. 2022; 307(2):331-341. DOI: 10.1007/s00404-022-06475-7. View